<DOC>
	<DOCNO>NCT01284413</DOCNO>
	<brief_summary>The objective study evaluate safety GCS therapy phase I efficacy GCS therapy phase II .</brief_summary>
	<brief_title>Gemcitabine/Cisplatin/S-1 ( GCS ) Combination Therapy Patients With Advanced Biliary Tract Cancer</brief_title>
	<detailed_description>Biliary tract cancer one lethal malignancy worldwide , surgery represent potentially curative treatment disease . However , many patient diagnose late curative resection , even surgery perform , likelihood relapse high . Over past decade , gemcitabine widely use treat unresectable recurrent biliary tract cancer patient . In ABC-02 study , first prospective multicenter phase III study field , gemcitabine/cisplatin combination chemotherapy compare gemcitabine monotherapy find combination regimen significantly prolong MST ( 8.1 11.7 month ; P &lt; 0.001 ) . Gemcitabine/cisplatin combination therapy consider standard regimen advance biliary tract cancer . S-1 oral fluoropyrimidine prodrug confirm efficacy various solid tumor , alone combination cytotoxic drug . S-1 monotherapy yield good result advance biliary tract cancer gemcitabine/S-1 combination therapy yield promising result acceptable toxicity level patient advance biliary tract cancer . In study , aim determine safety efficacy add S-1 gemcitabine/cisplatin combination regimen advance biliary tract cancer .</detailed_description>
	<mesh_term>Biliary Tract Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>1 . Patients cytologically histologically proved biliary tract cancer 2. age &gt; =20 year 3 . PS 02 4 . No prior history chemotherapy radiotherapy . Patients undergone adjuvant chemotherapy eligible least 6 month pass since last administration . 5 . Adequate bone marrow function ( neutrophil count &gt; =1,500/mm3 , platelet count &gt; =100,000/mm3 ) , liver function ( total bilirubin &gt; =3 mg/dL AST/ALT &gt; =150 IU/L ) , renal function ( creatinine clearance &gt; =60 mL/min ) 6.No serious comorbid disease 7.Adequate oral intake 8.Provided write informed consent 1 . Patients interstitial pneumonia pulmonary fibrosis 2 . Patients uncontrollable diabetes mellitus , liver disease , angina pectoris new onset myocardial infarction within 3 month 3 . Patients severe active infection 4 . Patients pregnant lactating , intention get pregnant 5 . Patients history severe drug allergy 6 . Patients serious comorbid disease 7 . Patients mental disease 8 . Patients judge inappropriate entry study principle doctor 9 . Patients watery diarrhea</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>